×
About 2,163 results

ALLMedicine™ Inflammatory Breast Cancer Center

Research & Reviews  1,015 results

Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077918
Genome Medicine; Li X, Kumar S et. al.

Apr 27th, 2021 - Inflammatory breast cancer (IBC) has a highly invasive and metastatic phenotype. However, little is known about its genetic drivers. To address this, we report the largest cohort of whole-genome sequencing (WGS) of IBC cases. We performed WGS of 2...

Small extracellular vesicle-encapsulated miR-181b-5p, miR-222-3p and let-7a-5p: Next ge...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075236
PloS One; Ahmed SH, Espinoza-Sánchez NA et. al.

Apr 26th, 2021 - Inflammatory breast cancer (IBC) is a rare, but aggressive entity of breast carcinoma with rapid dermal lymphatic invasion in young females. It is either poorly or misdiagnosed as mastitis because of the absence of a distinct lump. Small extracell...

New Treatment Strategies for the Inflammatory Breast Cancer.
https://doi.org/10.1007/s11864-021-00843-2 10.1007/s10549-015-3436-x 10.3233/BD-2006-22105 10.1093/jnci/dji172 10.1067/j.cpradiol.2006.12.001 10.1200/JCO.2003.07.082 10.1002/cncr.22927 10.1053/j.seminoncol.2007.11.018 10.1093/jnci/djt206 10.1093/jnci/djg022 10.1038/nrc1387 10.1054/bjoc.2000.1672 10.1371/journal.pone.0114559 10.1002/cncr.25179 10.1016/j.virol.2003.09.027 10.1148/radiol.2233010198 10.3233/BD-2006-22106 10.1007/s10549-007-9671-z 10.1007/s11547-010-0590-4 10.1007/s12282-012-0346-1 10.1016/j.clbc.2014.05.005 10.2967/jnumed.112.106864 10.2967/jnumed.108.056010 10.1002/cncr.24534 10.1053/j.seminoncol.2007.11.013 10.1016/j.breast.2003.08.004 10.1002/ijc.2910620404 10.1007/s10549-018-4835-6 10.1002/1097-0142(20011001)92:7<1775::AID-CNCR1693>3.0.CO;2-E 10.1007/s00432-016-2281-6 10.1007/s10549-019-05219-7 10.1016/S1470-2045(14)70080-4 10.1093/annonc/mdt182 10.21037/gs.2018.08.04 10.1016/j.breast.2017.06.002 10.1200/JCO.2014.55.1978 10.1053/j.seminoncol.2007.11.009 10.1056/NEJMoa1814017 10.1056/NEJMoa1612645 10.1056/NEJMoa1910549 10.1158/1078-0432.CCR-12-2549 10.1038/ncb1973 10.1186/s13058-018-1007-x 10.1007/s10549-015-3592-z 10.1002/1878-0261.12621 10.1093/annonc/mdm060 10.18632/oncotarget.18958 10.1001/jamaoncol.2018.1436 10.1158/1535-7163.MCT-15-0353 10.1073/pnas.1018866109 10.1038/nrclinonc.2009.73 10.1200/JCO.2010.30.5037 10.1200/JCO.2017.77.2665 10.1007/s40265-017-0701-9 10.1126/science.1071545 10.1016/j.clbc.2015.11.006 10.1002/1878-0261.12621 10.1074/jbc.M710038200 10.1016/S1470-2045(19)30689-8 10.18632/oncotarget.3642 10.1186/s13058-019-1108-1 10.1056/NEJMoa1910549 10.1056/NEJMoa040766 10.18632/oncotarget.10290 10.1093/annonc/mdw535
Current Treatment Options in Oncology; Vagia E, Cristofanilli M

Apr 24th, 2021 - Inflammatory breast cancer (IBC) remains the most aggressive type of breast cancer. During the past decade, enormous progress has been made to refine diagnostic criteria and establish multimodality treatment strategies as keys for the improvement ...

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy f...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051801
PloS One; Chainitikun S, Espinosa Fernandez JR et. al.

Apr 16th, 2021 - The current use of targeted therapy plus neoadjuvant chemotherapy for inflammatory breast cancer (IBC) is based on data extrapolated from studies in non-IBC. We conducted a systematic review to determine whether neoadjuvant chemotherapy plus targe...

Inflammatory breast cancer: early recognition and diagnosis is critical.
https://doi.org/10.1016/j.ajog.2021.04.217
American Journal of Obstetrics and Gynecology; Hester RH, Hortobagyi GN et. al.

Apr 12th, 2021 - Inflammatory breast cancer (IBC) is a rare and aggressive malignancy that is often initially misdiagnosed due to its similar presentation to more benign breast pathology such as mastitis, resulting in treatment delays. Presenting symptoms of IBC i...

see more →

Guidelines  1 results

International expert panel on inflammatory breast cancer: consensus statement for stand...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105293
Annals of Oncology : Official Journal of the European Soc... Dawood S, Merajver SD et. al.

Jul 6th, 2010 - Inflammatory breast cancer (IBC) represents the most aggressive presentation of breast cancer. Women diagnosed with IBC typically have a poorer prognosis compared with those diagnosed with non-IBC tumors. Recommendations and guidelines published t...

see more →

Clinicaltrials.gov  1,087 results

Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077918
Genome Medicine; Li X, Kumar S et. al.

Apr 27th, 2021 - Inflammatory breast cancer (IBC) has a highly invasive and metastatic phenotype. However, little is known about its genetic drivers. To address this, we report the largest cohort of whole-genome sequencing (WGS) of IBC cases. We performed WGS of 2...

Small extracellular vesicle-encapsulated miR-181b-5p, miR-222-3p and let-7a-5p: Next ge...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075236
PloS One; Ahmed SH, Espinoza-Sánchez NA et. al.

Apr 26th, 2021 - Inflammatory breast cancer (IBC) is a rare, but aggressive entity of breast carcinoma with rapid dermal lymphatic invasion in young females. It is either poorly or misdiagnosed as mastitis because of the absence of a distinct lump. Small extracell...

New Treatment Strategies for the Inflammatory Breast Cancer.
https://doi.org/10.1007/s11864-021-00843-2 10.1007/s10549-015-3436-x 10.3233/BD-2006-22105 10.1093/jnci/dji172 10.1067/j.cpradiol.2006.12.001 10.1200/JCO.2003.07.082 10.1002/cncr.22927 10.1053/j.seminoncol.2007.11.018 10.1093/jnci/djt206 10.1093/jnci/djg022 10.1038/nrc1387 10.1054/bjoc.2000.1672 10.1371/journal.pone.0114559 10.1002/cncr.25179 10.1016/j.virol.2003.09.027 10.1148/radiol.2233010198 10.3233/BD-2006-22106 10.1007/s10549-007-9671-z 10.1007/s11547-010-0590-4 10.1007/s12282-012-0346-1 10.1016/j.clbc.2014.05.005 10.2967/jnumed.112.106864 10.2967/jnumed.108.056010 10.1002/cncr.24534 10.1053/j.seminoncol.2007.11.013 10.1016/j.breast.2003.08.004 10.1002/ijc.2910620404 10.1007/s10549-018-4835-6 10.1002/1097-0142(20011001)92:7<1775::AID-CNCR1693>3.0.CO;2-E 10.1007/s00432-016-2281-6 10.1007/s10549-019-05219-7 10.1016/S1470-2045(14)70080-4 10.1093/annonc/mdt182 10.21037/gs.2018.08.04 10.1016/j.breast.2017.06.002 10.1200/JCO.2014.55.1978 10.1053/j.seminoncol.2007.11.009 10.1056/NEJMoa1814017 10.1056/NEJMoa1612645 10.1056/NEJMoa1910549 10.1158/1078-0432.CCR-12-2549 10.1038/ncb1973 10.1186/s13058-018-1007-x 10.1007/s10549-015-3592-z 10.1002/1878-0261.12621 10.1093/annonc/mdm060 10.18632/oncotarget.18958 10.1001/jamaoncol.2018.1436 10.1158/1535-7163.MCT-15-0353 10.1073/pnas.1018866109 10.1038/nrclinonc.2009.73 10.1200/JCO.2010.30.5037 10.1200/JCO.2017.77.2665 10.1007/s40265-017-0701-9 10.1126/science.1071545 10.1016/j.clbc.2015.11.006 10.1002/1878-0261.12621 10.1074/jbc.M710038200 10.1016/S1470-2045(19)30689-8 10.18632/oncotarget.3642 10.1186/s13058-019-1108-1 10.1056/NEJMoa1910549 10.1056/NEJMoa040766 10.18632/oncotarget.10290 10.1093/annonc/mdw535
Current Treatment Options in Oncology; Vagia E, Cristofanilli M

Apr 24th, 2021 - Inflammatory breast cancer (IBC) remains the most aggressive type of breast cancer. During the past decade, enormous progress has been made to refine diagnostic criteria and establish multimodality treatment strategies as keys for the improvement ...

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy f...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051801
PloS One; Chainitikun S, Espinosa Fernandez JR et. al.

Apr 16th, 2021 - The current use of targeted therapy plus neoadjuvant chemotherapy for inflammatory breast cancer (IBC) is based on data extrapolated from studies in non-IBC. We conducted a systematic review to determine whether neoadjuvant chemotherapy plus targe...

Inflammatory breast cancer: early recognition and diagnosis is critical.
https://doi.org/10.1016/j.ajog.2021.04.217
American Journal of Obstetrics and Gynecology; Hester RH, Hortobagyi GN et. al.

Apr 12th, 2021 - Inflammatory breast cancer (IBC) is a rare and aggressive malignancy that is often initially misdiagnosed due to its similar presentation to more benign breast pathology such as mastitis, resulting in treatment delays. Presenting symptoms of IBC i...

see more →

News  41 results

Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer?
https://reference.medscape.com/viewarticle/870990_3

Aug 9th, 2020 - When PET is combined with CT scanning to assist in anatomic localization, scans can identify axillary and nonaxillary (eg, internal mammary or supraclavicular) lymph node metastasis for the purposes of staging locally advanced and inflammatory bre...

Idiopathic Granulomatous Mastitis
https://www.mdedge.com/dermatology/article/192305/mixed-topics/idiopathic-granulomatous-mastitis/page/0/1

Jan 8th, 2019 - Idiopathic granulomatous mastitis (IGM) is rare during pregnancy; it typically is seen in women of childbearing potential from 6 months to 6 years postpartum. 1 Because of a temporal association with breastfeeding, it is believed that hyperprolacti.

Diagnosing Inflammatory Breast Cancer: Can We Get Everyone on the Same Page?
https://www.medscape.com/viewarticle/901881

Sep 17th, 2018 - Hi. This is Dr Kathy Miller from Indiana University, back with you again. Today I want to talk a bit about inflammatory breast cancer. I'm willing to bet that a scene that played out at our local tumor board a couple of weeks ago will sound famili...

EGFR Inhibitor Shows Signal in Triple-Negative Inflammatory Breast Ca
https://www.medpagetoday.com/hematologyoncology/breastcancer/73398

Jun 8th, 2018 - Adding panitumumab to a carboplatin-containing neoadjuvant chemotherapy regimen yielded a higher rate of pathologic complete response (pCR) in patients with triple-negative inflammatory breast cancer (IBC), a small study found. Among the 17 evalua...

Late toxicities with PARP inhibitor plus RT in inflammatory breast cancer
https://www.mdedge.com/hematology-oncology/article/161606/breast-cancer/late-toxicities-parp-inhibitor-plus-rt-inflammatory/page/0/1

Mar 23rd, 2018 - The investigators noted that, at year 3, severe fibrosis in the treatment field was seen in 6 of the 15 surviving patients. Of the six patients, two also had grade 3 skin induration, and two had grade 3 lymphedema.

see more →

Patient Education  19 results see all →